Awareness of Genomic Testing in Breast Cancer
Awareness of Genomic Testing in Breast Cancer – A Call to Action Across Europe
Cancer Patients Europe is leading an urgent call to action to ensure that breast cancer patients across Europe benefit from genomic testing and the latest progress in precision and personalised medicine. This will improve the management of patients and breast cancer outcomes, ultimately reducing the burden of breast cancer on both patients and healthcare systems.
Launched in 2022, myC (my Cancer my Concern) is a CPE initiative that aims to raise awareness of the benefits and values of genomic testing in cancer.
The project is part of our broader goal to improve the management of cancer patients across Europe. Personalised treatment decisions are central to this effort, and genomic testing is an example of current progress in this area.
Awareness and understanding of genomics and genomic testing are still in their infancy, especially in the patient community. To address this, we are undertaking a variety of initiatives, including patient surveys. Our aim is to raise awareness and urge action by EU policy makers for the benefit of cancer patients.
The data demonstrated an acute lack of awareness and understanding of genomic testing amongst both the general population and cancer patients as well as a lack of communication on the topic by healthcare professionals.
The results of this in-depth survey strongly highlight the need to raise awareness and understanding about the value and benefits of genomic testing in breast cancer among different stakeholder groups. Based on this compelling data, CPE is leading an urgent call to action to ensure that breast cancer patients across Europe benefit from genomic testing and the latest progress in precision and personalised medicine. This will improve the management of patients and breast cancer outcomes, ultimately reducing the burden of breast cancer on both patients and healthcare systems.